* BIOMEDICAL DIAGNOSTICS *
1986 - IDF
Marne-la-Vallée
(near Paris)
www.bmd-net.com Discovery, Diagnostics
(also, Design, Devices)
Key words: Auto-immune diseases, Allergy test monitor, Caris, Fidis, Luminex
Mission: to develop, manufacture and market quality and innovative IVD products for the diagnostic market of auto-immune diseases, allergies and infectious diseases
Clients: Pharmaceutical industry
bmd@bmd-net.com
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS | | Start-up |
Managing Dir.: Magrez (Paul) [born 1958, M.D., Ph.D. computer science (Bruxelles), ex-GSK, UCB, Innogenetics]
Sc.Dir.:
Fin.Dir.: Géricot (Laurence) [MBA, ex-Hewlett Packard]
BusDev:
Financers: Truffle Venture, CDC Entreprise, AGF P.E., Siparex, Auriga Partners, Ventech, 123 Multinova | Turnover (M€) : 15.6 (2006)
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Allergy
Position : Trade
Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME | | 2008 .10 | Financing (no interest loan) : 5.4 M€ (and 2.5 M€ grant), OSEO Innovation, to support Tracker, a theranostics project concerning rheumatoid arthritis from Neovacs (leader) and Biomedical Diagnostics | DEBT | [22 years] |
| 2007 .00 | Nomination : Paul Magrez, as CEO (replacing Patrick G. Poty) | ORGN | [21 years] |
| 2005 .07 | 3rd round-financing : 5.0 M€, led by Truffle Venture and CDC Entreprise, with AGF P.E., Siparex, Auriga Partners, Ventech, 123 Multinova | RFINC | [19 years] |
| 2004 .05 | Nomination : Patrick G. Poty, as CEO (Daniel Pierron on leave) | ORGN | [18 years] |
| 2003 .05 | 2nd round-financing : 9.4 M€, by undisclosed investors | RFINB | [17 years] |
| 2000 .05 | 1st round-financing : 4.6 M€, by undisclosed investors | RFINA | [14 years] |
| 1986 .00 | Company founded by 2 ex-Abbott managers | ORGF | [0 year] | Actualisation / Updating: 31-Oct-2008 |
|
